

GSK FINANCE (NO 2) LIMITED

registered in England under number 11724333 with its registered office at
980 Great West Road, Brentford, Middlesex, TW8 9GS (the "Company")

**STATEMENT OF COMPLIANCE UNDER SECTION 644(5) OF THE COMPANIES ACT 2006
MADE ON MONDAY 13 SEPTEMBER 2021**

1. This is a statement of the directors of the Company for the purposes of section 644(5) of the Companies Act 2006 (the "Act") and has been signed by each of the directors of the Company as at the date of this statement.
2. We, being each of the directors of the Company as at the date of this statement, confirm that the solvency statement dated Monday 13 September 2021 and made for the purposes of section 642 of the Act in the form as prescribed by the Companies (Reduction of Share Capital) Order 2008 was:
 - (A) made not more than 15 days before Monday 13 September 2021, being the date on which the special written resolution was passed resolving that an amount of USD 20,618,931,379.91 standing to the credit of its share premium account of the Company be cancelled and extinguished; and
 - (B) provided to the Company's sole eligible member in accordance with section 642(2) of the Act, that is, it was sent or submitted to the sole eligible member at or before the time at which the proposed special written resolution referred to in paragraph (A) above was sent or submitted to the sole eligible member.
3. This statement of the directors of the Company is made on Monday 13 September 2021.

[Signatures follow]

Signed:



.....
Iain Mackay, Director



.....
Adam Walker, Director



.....
John Sadler

For and on behalf of

Edinburgh Pharmaceutical Industries Limited, Corporate Director



.....
Sarah Ghinn

For and on behalf of

The Wellcome Foundation Limited, Corporate Director